Dernières nouvelles pour ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

ImmunityBio Inc

The board of directors of The Timken Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>, <a href="https://c212.net/c/link/?t=0&amp;amp, , %20l=en&amp;amp, , %20o=4418386-1&amp;amp, , %20h=3010813979&amp;amp, , %20u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3856973-1%26h%3D2432425124%26u%3Dhttp%253A%252F%252Fwww.timken.com%252F%26a%3Dwww.timken.com&amp;amp, , %20a=www.timken.com">www.timken.com</a>))), a global technology leader in engineered bearings and industrial motion, today approved a 3 percent increase in the company's quarterly cash dividend, raising it to 35 cents&nbsp;per share. The dividend is payable on&nbsp;May 23, 2025, to shareholders of record as of&nbsp;May 13, 2025.

News

Dividends

Timken Board Raises Quarterly Cash Dividend By 3% From $0.34 To $0.35 Per Share

Government

Macro Economic Events

Politics

Economics

General

Iran Foreign Ministry Says Tehran Rejects 'Threats And Pressure' After US President Trump Said All Purchases Of Iranian Oil Or Petrochemicals Products Must Stop

Rosenblatt analyst Barton Crockett maintains Emerald Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) with a Buy and maintains $7.8 price target.

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Emerald Holding, Maintains $7.8 Price Target

Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYA#NASDAQ">LBTYA</a>) reported quarterly losses of $(3.84) per share which missed the analyst consensus estimate of $(0.44) by 772.73 percent. This is a 340 percent decrease over earnings of $1.60 per share from the same period last year. The company reported quarterly sales of $1.17 billion which beat the analyst consensus estimate of $1.11 billion by 5.93 percent. This is a 7.42 percent increase over sales of $1.09 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

LBTYA

Liberty Global Q1 EPS $(3.84) Misses $(0.44) Estimate, Sales $1.17B Beat $1.11B Estimate

Arbor Realty Trust Q1 Adj. EPS $0.31 Beats $0.27 Estimate, Sales $75.44M Miss $77.17M Estimate

Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia
Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques
ReShape Lifesciences&#xAE; (NASDAQ:<a href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the premier physician-led weight loss and metabolic health solutions company, today announced it will present pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium, being held in Minneapolis.
Poster Presentation Details:
<ul>
<li>Poster Title: Stimulation of the Posterior Sub-Diaphragmatic Vagal Trunk Reverses Insulin-Induced Severe Hypoglycemia in a Swine Model of Type 1 Diabetes Mellitus</li>
<li>Poster Number: 3308</li>
<li>Author: Jonathan J. Waataja, Ph.D., Director of Research at ReShape Lifesciences&#xAE;</li>
<li>Session: Session B</li>
<li>Date: May 2, 2025</li>
<li>Time: 10:45 am -1:00 pm CT</li>
</ul>
"Hypoglycemia remains a significant barrier to effective diabetes management, contributing to severe health risks and reduced quality of life," stated Dr. Waataja. "Our Diabetes Neuromodulation technology utilizes Hypoglycemia Vagus Nerve Stimulation (HVNS), targeting stimulation of the sub-diaphragmatic posterior vagus nerve (PVN) to rapidly increase blood glucose (BG) during hypoglycemic episodes. The ability to avoid cardiac side effects while effectively mitigating BG is critical for clinical viability. Unlike conventional vagal stimulation techniques, our targeted HVNS approach alters glucose levels without impacting heart rate, blood pressure or respiration, overcoming a key limitation of conventional vagal stimulation techniques. Also, sub-diaphragmatic stimulation does not affect speech, which is an obstacle to increasing desired therapeutic levels with conventional vagal stimulation. The pre-clinical data presented today paves the way for the continued development of our proprietary technology aimed at reducing dependence on injections and wearable glucose monitors, with the potential to dramatically improve quality of life for people with Type 1 or Type 2 diabetes."
Designed to evaluate HVNS efficacy and off-target systemic effects in a Type 1 diabetic swine model, laparoscopic placement of an electrode on the PVN successfully increased blood glucose levels and glucagon secretion without impacting cardiac output. Following insulin-induced hypoglycemia (blood glucose &lt;55 mg/dL), HVNS elevated glucose from a baseline of 45 to 58 mg/dL in one swine and from 51 to 68 mg/dL in another after 30 minutes of stimulation. Correspondingly, blood glucagon levels rose from 4.1 to 12.3 pmol/L and from 3.5 to 7.6 pmol/L. Importantly, mean heart rate remained stable, with no significant changes observed during stimulation. Vomiting was only observed at current amplitudes (~6 mA) above those needed to elicit therapeutic glucose changes (~3 mA), underscoring a clear therapeutic window. Positive control tests using intramuscular glucagon produced similar blood glucose increases, further validating HVNS as an effective alternative.
"The presentation of this data at such an important industry conference is a testament to the strength of the pre-clinical evidence showing the potential effectiveness of our proprietary Diabetes Neuromodulation device," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. "As demonstrated in this model, our technology offers a fast-acting, device-based intervention for insulin-induced hypoglycemia. Given the promise of this approach, we will continue to seek non-dilutive funding, while simultaneously working with top researchers and industry leading strategic corporate partners to potentially bring this novel therapeutic to market."
About The ReShape Diabetes Neuromodulation Device The ReShape Diabetes Neuromodulation system (formerly, Diabetes Bloc-Stim Neuromodulation&#x2122; (DBSN&#x2122;) is a novel minimally invasive therapeutic implant concept that delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The system utilizes a proprietary, reversable and adjustable electrical blockade that may represent the future of personalized medicine. Reshape Lifesciences believes its system is superior to both standalone stimulation of the vagus nerve, and vagus nerve ligation which has undesirable side effects and causes irreversible damage to the nerve.

Biotech

RSLS

ReShape Lifesciences Announces It Will Present Pre-Clinical Data On Its Proprietary Diabetes Neuromodulation Device in Poster Presentation At 12th Annual Minnesota Neuromodulation Symposium May 2, 2025

Rosenblatt analyst Mike Genovese maintains Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) with a Neutral and maintains $40 price target.

JNPR

Rosenblatt Maintains Neutral on Juniper Networks, Maintains $40 Price Target

HC Wainwright &amp; Co. analyst Mike Colonnese maintains Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $480 to $521.

MSTR

HC Wainwright & Co. Maintains Buy on Strategy, Raises Price Target to $521

Baird analyst Mike Polark maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Outperform and raises the price target from $133 to $150.

IRTC

Baird Maintains Outperform on iRhythm Technologies, Raises Price Target to $150

Forge Global Holdings, Inc. ("Forge") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>), a leading provider of marketplace infrastructure, data services, and technology and investment solutions for the private market, today announced that it has regained compliance with the New York Stock Exchange ("NYSE") continued listing criteria for minimum share price under Section 802.01C of the NYSE Listed Company Manual.
On May 1, 2025, the NYSE provided Forge with a notification letter of compliance based on Forge's closing share price on April 30, 2025, as well as a calculation of Forge's average closing share price for the 30 trading days ended April 30, 2025, which reflected an average closing share price above the NYSE's $1.00 minimum requirement. Accordingly, it has regained compliance with the minimum share price requirement of Section 802.01C.
Forge's common stock will continue to be listed and trade on the NYSE, subject to the Company's compliance with other NYSE continued listing standards.

FRGE

Forge Global Holdings Regains Compliance With NYSE Continued Listing Standard

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $192 to $160.

ICLR

Baird Maintains Neutral on Icon, Lowers Price Target to $160

Franklin Resources Q2 Adj. EPS $0.47 Misses $0.49 Estimate, Sales $2.11B Beat $1.59B Estimate

Econ #s

Participation Rate (Apr):	62.6% vs 62.5% Prior

USA Private Nonfarm Payrolls For April 167K Vs 124K Est.; 170K Prior

USA Average Hourly Earnings (MoM) (Apr) 0.2% Vs 0.3% Est; 0.3% Prior

Baird analyst Catherine Schulte maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and raises the price target from $69 to $72.

EXAS

Baird Maintains Outperform on Exact Sciences, Raises Price Target to $72

Nonfarm Payrolls For April 177K Vs 138K Expected; 228K Prior

Macro Notification

US Unemployment Rate (Apr): 4.2% vs 4.2% Est.

Rosenblatt analyst Kevin Garrigan maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Neutral and maintains $644 price target.

MPWR

Rosenblatt Maintains Neutral on Monolithic Power Systems, Maintains $644 Price Target

WestPark Capital analyst Curtis Shauger reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and maintains $280 price target.

Reiteration

AMZN

WestPark Capital Reiterates Buy on Amazon.com, Maintains $280 Price Target

Press Releases

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, LLP Investigates Claims on Behalf of Investors

Legal

Investor Alert: Wolfspeed, Driven Brands Holdings, Hasbro, and ImmunityBio: Johnson Fistel, PLLP Investigates Claims on Behalf of Investors

ImmunityBio to Host Investor Day

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Comments

ImmunityBio

Actualités

Dernières nouvelles pour ImmunityBio (NASDAQ:IBRX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL